In phase 2 trial, novel therapy significantly reduced triglyceride levels
A phase 2b clinical trial led by Mass General Brigham Heart and Vascular Institute researchers shows that a monoclonal antibody therapy called MAR001 can significantly reduce triglyceride levels within ...
9 Nov 14:00 · Medical Xpress